EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

A safety comparison of heparin and argatroban anticoagulation in veno‐venous extracorporeal membrane oxygenation with a focus on bleeding

Filip Burša iD, Jan Máca, Jiří Sagan, Peter Sklienka, Simona Němcová, Zuzana Kučerová, Tereza Romanová, Ondřej Jor, Adéla Kondé, Jaroslav Janošek, Michal Frelich

Transfusion Medicine · 2025

DOI: 10.1111/tme.13102 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transfusion Medicine, 2025. Verfasst von Filip Burša und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Anticoagulants, COVID-19, Extracorporeal Membrane Oxygenation, Hemorrhage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anticoagulation during extracorporeal membrane oxygenation (ECMO) might still lead to severe bleeding complications. Heparin is the most frequently used anticoagulant, but novel drugs could be promising. Argatroban is a new alternative to heparin. To date, no robust studies have confirmed the clear superiority of argatroban (AG) over heparin, although it has some advantages and may be safer. Study Design and Methods An observational study was conducted in all adult veno‐venous ECMO patients with COVID‐19‐associated acute respiratory distress syndrome admitted to the University Hospital Ostrava ( n = 63). They were anticoagulated with heparin in the first period and with AG in the second period, targeting the same activated partial thromboplastin time (aPTT; 45–60 s). Bleeding complications requiring transfusion and life‐threatening bleeding events were evaluated. The primary objective was to compare heparin and AG in terms of bleeding, transfusion requirements and mortality‐related bleeding.

Results

The total time on ECMO per patient was 16 days with an in‐hospital mortality of 55.6%. The red blood cell consumption in the AG group (median 2.7 transfusions/week) was significantly lower than in the heparin group (median 4.2 transfusions/week, p = 0.011). Life‐threatening bleeding complications were higher in the heparin group compared to the AG group (35.7% vs. 10.2%, p = 0.035 ), and mortality‐related bleeding complications were also higher in the heparin group (21.4% vs. 2.0%, p = 0.032).

Discussion

Argatroban is an interesting alternative to heparin with less bleeding, less need for red blood cell transfusions and improved safety of ECMO with less mortality‐related bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsCOVID-19Extracorporeal Membrane OxygenationHemorrhageHeparinPipecolic AcidsSulfonamidesAdultAgedFemaleHumansMaleMiddle AgedArginineSARS-CoV-2

Stichwörter der Autor:innen

anticoagulationargatrobanbleedingextracorporeal membrane oxygenation (ECMO)heparin

Substanzen

AnticoagulantsargatrobanArginineHeparinPipecolic AcidsSulfonamides

Autor:innen und Institutionen

  • Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
  • Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Department of Infectious Diseases, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB- Technical University of Ostrava, Ostrava, Czech Republic.
  • Department of the Deputy Director for Science, Research and Education, University Hospital Ostrava, Ostrava, Czech Republic.
  • Center for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

ORCID-Profile: Filip Burša

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Burša, F., Máca, J., Sagan, J., Sklienka, P., Němcová, S., Kučerová, Z., Romanová, T., Jor, O., Kondé, A., Janošek, J., & Frelich, M. (2025). A safety comparison of heparin and argatroban anticoagulation in veno‐venous extracorporeal membrane oxygenation with a focus on bleeding. Transfusion Medicine. https://doi.org/10.1111/tme.13102

Vancouver

Burša F, Máca J, Sagan J, Sklienka P, Němcová S, Kučerová Z, et al. A safety comparison of heparin and argatroban anticoagulation in veno‐venous extracorporeal membrane oxygenation with a focus on bleeding. Transfusion Medicine. 2025. doi:10.1111/tme.13102

BibTeX
@article{Bura2025,
  author = {Burša, Filip and Máca, Jan and Sagan, Jiří and Sklienka, Peter and Němcová, Simona and Kučerová, Zuzana and Romanová, Tereza and Jor, Ondřej and Kondé, Adéla and Janošek, Jaroslav and Frelich, Michal},
  title = {A safety comparison of heparin and argatroban anticoagulation in veno‐venous extracorporeal membrane oxygenation with a focus on bleeding},
  journal = {Transfusion Medicine},
  year = {2025},
  doi = {10.1111/tme.13102}
}
Kostenlos starten →